Acute Lymphoblastic Leukemia (ALL)

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation

By

Despite its high response rate, researchers are finding that patients with endothelial activation prior to lymphodepletion chemotherapy are at greater risk of neurologic adverse events after undergoing CAR T-cell therapy for relapsed/refractory B-ALL, CLL, or NHL.

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

Two FDA Approvals Propel CAR T Cell Therapy Into the Limelight

By

The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia

By

Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

Current, Emerging Systemic and Targeted Therapies for Pediatric Leukemia: A Review

By

In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

Pediatric Acute Lymphoblastic Leukemia Extramedullary Relapse Responds to CAR-T

By

Children with extramedullary relapse of CD19+ acute lymphoblastic leukemia experienced a potent and durable response to the immunotherapy.

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

By

The site of cancer care may partially explain survival differences between children and AYAs with ALL.

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

By

Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.

Two Infants Achieve Leukemia Remission After Gene Therapy

Two Infants Achieve Leukemia Remission After Gene Therapy

By

Two infants with advanced acute lymphoblastic leukemia (ALL) achieved full remission following gene therapy involving modified autologous CAR-T cells.

Prenatal Herpes Virus Infection May Increase Childhood Leukemia Risk

Prenatal Herpes Virus Infection May Increase Childhood Leukemia Risk

By

Study results indicate that herpetic cytomegalovirus infection prior to birth subjects the child to increased odds of developing pediatric acute lymphoblastic leukemia.

Study Identifies Factors Associated With Infection-related Complications in ALL

Study Identifies Factors Associated With Infection-related Complications in ALL

By

Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.

Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer

Internalizing, Externalizing Behavioral Problems a Significant Postdiagnosis Concern in Children With Cancer

By

Children with cancer are at risk for developing behavioral problems after diagnosis.

Hyper-CVAD + Ponatinib May Be Superior to Hyper-CVAD + Dasatinib in Ph+ ALL

By

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

Post-transplant Maintenance TKIs Beneficial for Patients With High-risk Ph+ Leukemia

By

A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

Intensive Protocol Improves Survival for Adults with Acute Lymphoblastic Leukemia

By

Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.

Blinatumomab Improves Overall Survival in Acute Lymphoblastic Leukemia

By

Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

Higher Concentrations of Methotrexate for Pediatric Leukemia Affect Long-Term Cognitive Processes

By

Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic Leukemia

By

Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

Challenges faced in the treatment of acute lymphoblastic leukemia in adolescents and young adults

[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.

Anxiety and Depressive Symptoms Are Increased in Pediatric Survivors of Acute Lymphoblastic Leukemia

By

Emotional distress during and after undergoing chemotherapy for ALL affects a significant percentage of children with the disease.

New Possible Treatment Addresses Specific Type of Leukemia

By

A subtype-specific weakness of T-cell acute lymphoblastic leukemia (T-ALL) could enable improved treatment, according to results from a a recent study using a mouse model.

Study Findings Show Possible Association Between PreLabor Cesarean Delivery and Risk for ALL in Young Children

By

The finding that prelabor cesarean delivery may have a correlation with acute lymphoblastic leukemia (ALL) may offer new targets for research into preventing cancer.

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

Early Lineage T Cells Are Better for Immunotherapy in Pediatric Patients With ALL and Lymphoma

By

Outcomes from a novel personalized cell therapy may be improved if specific subtypes of T cells are selected to attack diseases such as acute lymphoblastic leukemia and lymphoma.

Long-term Attention and Learning Deficits Persist After Chemotherapy for Pediatric Leukemia

By

Pediatric survivors of ALL treated only with chemotherapy remain at an increased risk for attention problems 2 years after treatment cessation.

Chromosomal Rearrangements Initiate High-risk Leukemia

By

Abnormal breakage and chromosomal rearrangement in white blood cells result in a particularly aggressive Philadelphia chromosome-like ALL, according to a new study.

Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed

Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed

By

Significant bone loss in children receiving chemotherapy for acute lymphoblastic leukemia (ALL) occurs during the first month of treatment.

Treatment-related Anxiety for Pediatric Patients with Acute Lymphoblastic Leukemia Examined

Treatment-related Anxiety for Pediatric Patients with Acute Lymphoblastic Leukemia Examined

By

A new study examined levels of procedure-related anxiety in children with standard-risk acute lymphoblastic leukemia (ALL).

Association Is Found Between Bone Complications in Young Pediatric Patients With Leukemia and Gene Variations

By

Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL).

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

By

Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

By

Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

By

A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs